Benitec's BB-301 Gene Therapy Shows Robust High-Dose Efficacy, Durable Improvements in OPMD Trial
BNTC sits 22% above its 52-week low of $9.85.
Summary
Benitec Biopharma announced highly positive interim Phase 1b/2a clinical trial results for its BB-301 gene therapy in patients with Oculopharyngeal Muscular Dystrophy (OPMD). The data, presented at the MDA conference, showed significant and durable improvements in swallowing function for both low and high dose cohorts. Notably, the first patient treated with the high dose experienced an "extraordinarily robust dose-response" at an early follow-up, indicating strong potential for disease-modifying outcomes. This is a critical de-risking event for Benitec, as BB-301 is the only clinical-stage therapeutic targeting dysphagia in OPMD, addressing a significant unmet medical need. These results provide strong validation for the company's pipeline and could significantly impact its valuation. Investors will now watch for further data readouts and the program's progression into later-stage clinical development.
At the time of this announcement, BNTC was trading at $12.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $389.6M. The 52-week trading range was $9.85 to $17.15. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.